{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:34:33Z","timestamp":1761766473096},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Iatrogenic lymphoproliferative disorders have been described in patients receiving immunosuppressive\/immunomodulatory agents outside the transplantation setting. Novel biological agents such as TNF-\u03b1 blockers and JAK-inhibitors have also proven to be effective in many disorders including rheumatoid arthritis, inflammatory bowel disease (ulcerative colitis and Crohn disease), psoriasis, and others. A significant dilemma exists in those lymphoproliferative disorders associated with immunosuppressants and rheumatologic conditions, that relies on whether the association of the process is with the medication or the underlying autoimmune condition. In the current case report, we describe an extraordinary case of Epstein-Barr virus\u2013positive anaplastic large cell lymphoma, in association with rheumatoid arthritis and the use of JAK-inhibitors. Comprehensive molecular testing (fluorescence in situ hybridization, OncoScan microarray, pyrosequencing) was done comparing sequential biopsies in this patient from skin and lung, which revealed a driving mutation in the<jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>gene, a crucial finding, given the potential use of targeted therapy in this pathway.<\/jats:p>","DOI":"10.1097\/pas.0000000000001174","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T08:48:31Z","timestamp":1539593311000},"page":"140-146","source":"Crossref","is-referenced-by-count":10,"title":["An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation"],"prefix":"10.1097","volume":"43","author":[{"given":"Alejandro A.","family":"Gru","sequence":"first","affiliation":[{"name":"Pathology & Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Williams","sequence":"additional","affiliation":[{"name":"Pathology, University of Virginia, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Junkins-Hopkins","sequence":"additional","affiliation":[{"name":"Dermatopathology, Geisinger Medical Laboratories, Danville, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.semdp.2012.08.005","article-title":"Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders","volume":"30","author":"Bagg","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/modpathol.2009.131","article-title":"Immunomodulator agent-related lymphoproliferative disorders","volume":"22","author":"Hasserjian","year":"2009","journal-title":"Mod Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archderm.1997.03890430083011","article-title":"Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis","volume":"133","author":"Paul","year":"1997","journal-title":"Arch Dermatol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J Clin Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer\u2014a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/bjd.13705","article-title":"Mycosis fungoides in the era of antitumour necrosis factor-alpha treatments","volume":"173","author":"Nikolaou","year":"2015","journal-title":"Br J Dermatol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ajcp\/aqw213","article-title":"T- and NK-cell lymphomas and systemic lymphoproliferative disorders and the immunodeficiency setting: 2015 SH\/EAHP Workshop Report-Part 4","volume":"147","author":"Gratzinger","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/ajt.12281","article-title":"Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series","volume":"13","author":"Seckin","year":"2013","journal-title":"Am J Transplant"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3109\/10428194.2014.889821","article-title":"Challenges and new prospects in hepatosplenic gammadelta T-cell lymphoma","volume":"55","author":"Calvaruso","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","article-title":"Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk","volume":"23","author":"Parakkal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/acr.23421","article-title":"Lymphoma in the Tofacitinib rheumatoid arthritis clinical development program","volume":"70","author":"Mariette","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/dc.21176","article-title":"Fine needle aspiration cytology of ALK1(\u2212), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review","volume":"38","author":"Balachandran","year":"2010","journal-title":"Diagn Cytopathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2340\/00015555-0543","article-title":"Primary cutaneous CD30+ anaplastic large cell lymphoma in a heart transplant patient: case report and literature review","volume":"89","author":"Belloni-Fortina","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/j.1365-2230.2008.03145.x","article-title":"Spontaneous regression of primary cutaneous Epstein-Barr virus-positive, CD30-positive anaplastic large T-cell lymphoma in a heart-transplant recipient","volume":"34","author":"Chiu","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1046\/j.1365-2133.2003.05441.x","article-title":"Primary cutaneous large cell CD30+ lymphoma in a renal transplant recipient","volume":"149","author":"Cooper","year":"2003","journal-title":"Br J Dermatol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2559.2004.01847.x","article-title":"Post-transplant T-cell lymphoproliferative disorder\/T-cell lymphoma: a report of three cases of T-anaplastic large-cell lymphoma with cutaneous presentation and a review of the literature","volume":"44","author":"Coyne","year":"2004","journal-title":"Histopathology"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1365-2133.2005.06535.x","article-title":"Posttransplant primary cutaneous CD30 (Ki-1)-positive anaplastic large T-cell lymphoma. A case report","volume":"152","author":"De Nisi","year":"2005","journal-title":"Br J Dermatol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.5858\/2004-128-e96-PPCKCA","article-title":"Posttransplant primary cutaneous Ki-1 (CD30)+\/CD56+ anaplastic large cell lymphoma","volume":"128","author":"Kim","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1111\/j.1600-6143.2004.00586.x","article-title":"EBV positive primary cutaneous CD30+ large T-cell lymphoma in a heart transplanted patient: case report","volume":"4","author":"Lucioni","year":"2004","journal-title":"Am J Transplant"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1600-6143.2004.00521.x","article-title":"Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature","volume":"4","author":"Rajakariar","year":"2004","journal-title":"Am J Transplant"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.dad.0000154414.46851.18","article-title":"Primary \u201ccutaneous\u201d T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review","volume":"27","author":"Salama","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1600-0560.2009.01449.x","article-title":"Cutaneous presentation of post-renal transplant lymphoproliferative disorder: a series of four cases","volume":"37","author":"Salama","year":"2010","journal-title":"J Cutan Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/jid.2010.271","article-title":"Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach","volume":"131","author":"Sanchez-Schmidt","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"suppl","key":"R32-20230922","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1067\/mjd.2001.102667","article-title":"Posttransplantation primary cutaneous CD30 (Ki-1)-positive large-cell lymphoma","volume":"45","author":"Seckin","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5858\/2010-0507-RAR.1","article-title":"Anaplastic large cell lymphoma: twenty-five years of discovery","volume":"135","author":"Kinney","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/DAD.0000000000000266","article-title":"Extranodal marginal zone lymphoma-like presentations of angioimmunoblastic T-cell lymphoma: a T-cell lymphoma masquerading as a B-cell lymphoproliferative disorder","volume":"37","author":"Kaffenberger","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e31828f2322","article-title":"Loss of Foxp3 is associated with CD30 expression in the anaplastic large cell subtype of adult T-cell leukemia\/lymphoma (ATLL) in US\/Caribbean patients: potential therapeutic implications for CD30 antibody-mediated therapy","volume":"37","author":"Yao","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-62703-281-0_13","article-title":"Array-CGH analysis of cutaneous anaplastic large cell lymphoma","volume":"973","author":"Szuhai","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/jid.2009.270","article-title":"Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators","volume":"130","author":"van Kester","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.onc.1209898","article-title":"A genomic analysis of adult T-cell leukemia","volume":"26","author":"Choi","year":"2007","journal-title":"Oncogene"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-4608(02)00589-7","article-title":"Molecular cytogenetic aberrations in CD30+ anaplastic large cell lymphoma cell lines","volume":"138","author":"Gogusev","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ni1320","article-title":"Transcriptional repressor Blimp-1 regulates T cell homeostasis and function","volume":"7","author":"Martins","year":"2006","journal-title":"Nat Immunol"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/modpathol.2010.225","article-title":"Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies","volume":"24","author":"Wada","year":"2011","journal-title":"Mod Pathol"},{"key":"R46-20230922","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"key":"R47-20230922","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"key":"R48-20230922","first-page":"816","article-title":"Detection and significance of BRAF gene in mature T\/NK cell lymphoma","volume":"37","author":"Ma","year":"2015","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"R50-20230922","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/leu.2008.14","article-title":"BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias","volume":"22","author":"Davidsson","year":"2008","journal-title":"Leukemia"},{"key":"R51-20230922","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/bloodadvances.2017006593","article-title":"BRAF(V600E) accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia","volume":"1","author":"Tsai","year":"2017","journal-title":"Blood Adv"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201901000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T10:25:13Z","timestamp":1720693513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201901000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001174","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}